iNtRON Biotechnology, Inc. Stock: price and insider trades · South Korea
인트론바이오
No insider purchase over the last 90 days. The latest, by 윤성준, was filed 03 Jul 2026.
Who traded when
BuySale+2 other insiders
Since the insiders bought
- -22.5%Entry ₩3,600 · Close 30 Oct 2026 ₩2,790
- -6.8%Entry ₩2,995 · Close 30 Oct 2026 ₩2,790
- -14.2%Entry ₩3,250 · Close 30 Oct 2026 ₩2,790
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- 38,590 sharesKRXDART:20260703000375Canonical exit: 1 Oct 2026 (T+90)
- 38,590 sharesShareKRXDART:20260615000218Canonical exit: 13 Sept 2026 (T+90)
- 20,800 sharesShareKRXDART:20260319000656
- ●Executives0DART
- 18,763 sharesKRXDART:20260223003035Canonical exit: 21 May 2026 (T+90)
- 31,053 sharesShareKRXDART:20260223002894
- 7,000 sharesShareKRXDART:20260130000462
- 49,816 sharesShareKRXDART:20260120000282Canonical exit: 20 Apr 2026 (T+90)
- 98,968 sharesShareKRXDART:20260120000275
- 535 sharesShareKRXDART:20260106000522Canonical exit: 6 Apr 2026 (T+90)
- 1,000,000 sharesShareKRXDART:20251217000361
- 406,506 sharesKRXDART:20251217000378Canonical exit: 17 Mar 2026 (T+90)
- 10,833 sharesShareKRXDART:20250107000355Canonical exit: 7 Apr 2025 (T+90)
- 15,000 sharesKRXDART:20230811001614Canonical exit: 6 Nov 2023 (T+90)
- ●Executives0DART
- ●Executives0DART
- 100,000 sharesShareKRXDART:20230217001295
- 100,000 sharesShareKRXDART:20230217001305Canonical exit: 16 May 2023 (T+90)
- ●Executives0DART
- ShareKRXDART:20221025000329
- ShareKRXDART:20221025000322
- 15,000 sharesKRXDART:20221025000319Canonical exit: 23 Jan 2023 (T+90)
- 15,000 sharesKRXDART:20220504000730Canonical exit: 2 Aug 2022 (T+90)
25 of 40 declarations
About iNtRON Biotechnology, Inc.
윤성준, filed as 대량보유자, appears in 13 of the 38 filings at 인트론바이오 (iNtRON Biotechnology, Inc.), with 10 purchases and 2 sales. The health care company, from South Korea, is valued at KRW 94.1 billion, and insiders hold only 18.8%. The record counts 15 purchases, 6 sales and 17 filings of another kind. No amount is reported. 윤경원 (대표이사/부사장) filed 4, including 3 purchases, 김성우 (이사) 6, including 1 purchase, and 설재구 2, including 1 sale. The company 인트론바이오 appears in 8 filings. Two filers bought between June 15 and July 3, 2026. Filings run from March 10, 2021 to July 3, 2026: 12 in 2022, 10 in 2026, 7 in 2021, 6 in 2023 and 3 in 2025. The last twelve months count 12, including 6 purchases and 5 sales. Stored 90-day figures for 11 purchases show a median of minus 15.8% and 27% positive, which describes the past.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
